Last 12 months
Inside the activity.
0 purchase rows · 153 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 25 |
| Dec 2025 | 0 | 13 |
| Jan 2026 | 0 | 14 |
| Feb 2026 | 0 | 24 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 23 |
| Jun 2026 | 0 | 20 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2020 Filed Nov 19, 2020 00:38 UTC |
Cook Jennifer E.Director
|
Exercise / conversionCommon Stock | 3,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031548 · doc4.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 10,069 | $43.57 | $438,688.21 |
DisclosureSEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 3 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,468 F4 · price: Represents the weighted average sale price of the shares sold from $43.53 to $43.67 per share. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 58,299 | $42.91 | $2,501,545.96 |
DisclosureSEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 2 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,537 F3 · price: Represents the weighted average sale price of the shares sold from $42.53 to $43.52 per share. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 31,632 | $42.22 | $1,335,534.67 |
DisclosureSEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,268,836 F1 · price: Represents the weighted average sale price of the shares sold from $41.53 to $42.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 3 and 4. F2 · balance_after: Corrects ending balance which was previously overstated by 100 shares in the Reporting Person's Form 4 filings on May 21, 2020 and December 31, 2019. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:05 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030623 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:05 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,500 | $42.05 | $105,124.75 |
DisclosureSEC source: 0000899243-20-030623 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $42.00 to $42.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:05 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,500 | $17.00 | $42,500.00 |
DisclosureSEC source: 0000899243-20-030623 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000899243-20-030214 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,282 Underlying: Common Stock · 10,000 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
SaleCommon Stock | 500 | $38.92 | $19,457.80 |
DisclosureSEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $38.86 to $38.97 per share. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
SaleCommon Stock | 9,500 | $38.33 | $364,099.85 |
DisclosureSEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.80 to $38.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionCommon Stock | 10,000 | $1.05 | $10,500.00 |
DisclosureSEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,256 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,207 Underlying: Common Stock · 10,256 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 10,256 | $41.00 | $420,496.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 01:14 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionCommon Stock | 10,256 | $17.00 | $174,352.00 |
DisclosureSEC source: 0000899243-20-028659 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,745 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 7 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,282 Underlying: Common Stock · 6,745 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,236 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,236 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
SaleCommon Stock | 5,505 | $39.28 | $216,248.51 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $38.81 to $39.71 per share. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
SaleCommon Stock | 4,495 | $38.29 | $172,093.32 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,256 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.74 to $38.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionCommon Stock | 6,745 | $1.05 | $7,082.25 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionCommon Stock | 3,255 | $0.28 | $911.40 |
DisclosureSEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,463 Underlying: Common Stock · 10,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 10,000 | $38.00 | $380,000.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:05 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0000899243-20-026658 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · derivative · entry 8 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,766 Underlying: Common Stock · 6,000 shares Expires 2029-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · derivative · entry 7 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,042 Underlying: Common Stock · 6,000 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · derivative · entry 6 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,058 | $38.24 | $78,706.98 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · nonDerivative · entry 5 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $38.06 to $38.39 per share. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 12,442 | $37.59 | $467,750.77 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · nonDerivative · entry 4 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,626 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.00 to $37.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 6,000 | $0.34 | $2,040.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 6,000 | $0.16 | $960.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:57 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,500 | $17.00 | $42,500.00 |
DisclosureSEC source: 0000899243-20-026978 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 23:02 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 18,200 | $37.50 | $682,500.00 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 23:02 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 15,396 | $37.47 | $576,865.03 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,967 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $37.26 to $37.66 per share. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 23:02 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 65,661 | $36.68 | $2,408,589.93 |
DisclosureSEC source: 0000899243-20-026476 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,363 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $36.26 to $37.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · balance_after: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:07 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025962 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,000 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:07 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,500 | $42.01 | $105,024.25 |
DisclosureSEC source: 0000899243-20-025962 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $42.00 to $42.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:07 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,500 | $17.00 | $42,500.00 |
DisclosureSEC source: 0000899243-20-025962 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,099 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 5,099 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,901 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,586 Underlying: Common Stock · 4,901 shares Expires 2028-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionCommon Stock | 5,099 | $0.28 | $1,427.72 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 23:05 UTC |
HENDERSON MICHAEL THOMASChief Business Officer
|
Exercise / conversionCommon Stock | 4,901 | $0.16 | $784.16 |
DisclosureSEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:05 UTC |
SCHELLER RICHARD HDirector · See Remarks
|
SaleCommon Stock | 25,000 | $37.50 | $937,500.00 |
DisclosureSEC source: 0000899243-20-025693 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,427 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2020. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 22:38 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025366 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 22:38 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,500 | $37.06 | $92,651.75 |
DisclosureSEC source: 0000899243-20-025366 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.00 to $37.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 22:38 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,500 | $17.00 | $42,500.00 |
DisclosureSEC source: 0000899243-20-025366 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 20:05 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0000899243-20-025095 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,766 Underlying: Common Stock · 2,000 shares Expires 2029-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 20:05 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,000 | $35.02 | $70,047.00 |
DisclosureSEC source: 0000899243-20-025095 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $35.00 to $35.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 20:05 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,000 | $0.34 | $680.00 |
DisclosureSEC source: 0000899243-20-025095 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.